CAMP CAMP4 Therapeutics Corp.

  1. Stocks
  2. Healthcare
  3. NASDAQ: CAMP

Price (delayed)

$3.72

Market cap

$233.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.32

Enterprise value

$148.69M

?
Relative Growth: Rel. Growth: 25
Relative Strength: Rel. Strength: 34
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 18
Highlights
The gross profit has grown by 40% YoY and by 7% from the previous quarter
CAMP4 Therapeutics's revenue has increased by 40% YoY and by 7% from the previous quarter
CAMP's debt has plunged by 67% YoY but it is up by 12% from the previous quarter
The net income has shrunk by 107% YoY and by 24% QoQ
The company's EPS has shrunk by 106% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.camp4tx.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of CAMP

CAMP stock price

How has the CAMP4 Therapeutics stock price performed over time
Intraday
-10.36%
1 week
-3.63%
1 month
-16.96%
1 year
47.62%
YTD
-39.31%
QTD
-14.87%

Financial performance

How have CAMP4 Therapeutics's revenue and profit performed over time
Revenue
$4.22M
Gross profit
$4.22M
Operating income
-$52.88M
Net income
-$107.24M
Gross margin
100%
Net margin
-2,543.7%
The net income has shrunk by 107% YoY and by 24% QoQ
CAMP's net margin is down by 48% YoY and by 16% from the previous quarter
The gross profit has grown by 40% YoY and by 7% from the previous quarter
CAMP4 Therapeutics's revenue has increased by 40% YoY and by 7% from the previous quarter

Price vs fundamentals

How does CAMP's price correlate with its fundamentals

Growth

What is CAMP4 Therapeutics's growth rate over time

Valuation

What is CAMP4 Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
51.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.27
The company's EPS has shrunk by 106% YoY
The equity has dropped by 102% since the previous quarter and by 102% year-on-year
CAMP4 Therapeutics's revenue has increased by 40% YoY and by 7% from the previous quarter
CAMP's price to sales (P/S) is 14% higher than its last 4 quarters average of 49.9

Efficiency

How efficient is CAMP4 Therapeutics business performance
The ROE has plunged by 61% from the previous quarter
The company's return on sales fell by 48% YoY and by 16% QoQ
The return on assets has declined by 11% since the previous quarter and by 10% year-on-year

Dividends

What is CAMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAMP.

Financial health

How did CAMP4 Therapeutics financials performed over time
CAMP4 Therapeutics's total assets has surged by 82% YoY but it has decreased by 11% QoQ
CAMP's total liabilities is up by 26% since the previous quarter
The equity has dropped by 102% since the previous quarter and by 102% year-on-year
CAMP's debt has plunged by 67% YoY but it is up by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.